Nucleic Acid Amplification Testing Market Report 2024

This Nucleic Acid Amplification Testing market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The nucleic acid amplification testing market size has grown rapidly in recent years. It will grow from $8.33 billion in 2023 to $9.56 billion in 2024 at a compound annual growth rate (CAGR) of 14.7%. The growth during the historic period can be attributed to increased awareness of infectious disease diagnosis, the emergence of new pathogens, a shift towards personalized medicine, rising demand for point-of-care testing, and supportive regulatory approvals and guidelines.

The nucleic acid amplification testing market size is expected to see rapid growth in the next few years. It will grow to $16.77 billion in 2028 at a compound annual growth rate (CAGR) of 15.1%. The growth during the forecast period can be attributed to the rising incidence of infectious diseases, the need for large-scale testing capabilities, increasing private sector investments, a growing demand for rapid and accurate testing methods, and a heightened need for advanced diagnostic measures. Major trends include the integration of artificial intelligence (AI), advancements in wearable and implantable devices, expanding use in point-of-care testing, growth in personalized medicine, and integration with digital health technologies.

The rising incidence of infectious diseases is expected to drive the growth of the nucleic acid amplification testing (NAAT) market in the future. Infectious diseases are conditions caused by organisms that can spread directly or indirectly from one individual to another through various means, such as physical contact, airborne transmission, contaminated food or water, or insect-borne transmission. The rise in infectious diseases is influenced by factors like antibiotic resistance, climate change, shifts in human behavior, and changes in agricultural practices. Nucleic acid amplification testing (NAAT) quickly and accurately detects infectious pathogens, enabling prompt diagnosis and treatment, which helps in controlling the spread of diseases. For example, in October 2023, the Public Health Agency of Canada, a government agency, reported that during the 2022-2023 season, participating provinces and territories documented 4,216 hospitalizations related to influenza. As a result, the increasing incidence of infectious diseases is contributing to the growth of the NAAT market.

Key players in the nucleic acid amplification testing (NAAT) market are focusing on developing innovative solutions, such as in vitro diagnostics (IVD) assays, to screen donated blood for cytomegalovirus (CMV) using nucleic acid amplification technology (NAT) in accordance with the In Vitro Diagnostic Regulation (IVDR). An IVD assay is a test conducted on biological samples in a laboratory to detect diseases, conditions, or infections outside the body. For example, in June 2024, GFE, a Germany-based company, introduced the PoET CMV. PoET CMV is an IVD assay designed for the rapid and accurate detection of CMV infections. Its standout features include high sensitivity and specificity, enabling early diagnosis and effective monitoring of CMV in transplant recipients and immunocompromised individuals. The assay employs advanced molecular techniques to provide reliable results quickly, aiding in timely clinical decision-making.

In July 2024, Roche Holding AG acquired LumiraDx for an undisclosed amount. This acquisition allows Roche to expand its diagnostics portfolio and offer a wider range of immunoassay and clinical chemistry tests. LumiraDx, a UK-based provider of nucleic acid amplification testing, will enhance Roche's capabilities in providing thorough, high-value testing without the need for specialized cold storage. This makes it suitable for diverse healthcare settings and improves testing efficiency and patient outcomes, especially in primary care and underserved areas.

Major companies operating in the nucleic acid amplification testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Siemens Healthineers, Becton, Dickinson and Company, Laboratory Corporation of America Holdings, Quest Diagnostics, Agilent Technologies Inc., Grifols S.A., Hologic Inc., bioMerieux SA, QuidelOrtho Corporation, Bio-Rad Laboratories Inc., Cepheid Inc., GenScript Biotech Corporation, ARUP Laboratories, BGI Group, Promega Corporation, Meridian Bioscience Inc., Takara Bio Inc., Eiken Chemical Co. Ltd., New England Biolabs Inc., TwistDx Limited, Bioneer Corporation.

North America was the largest region in the nucleic acid amplification testing (NAAT) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nucleic acid amplification testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the nucleic acid amplification testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Nucleic acid amplification testing (NAAT) encompasses molecular techniques designed to detect and amplify specific deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) within a sample. It is widely employed to identify pathogens at early stages of infection due to its high sensitivity. Researchers utilize NAAT to investigate gene expression, genetic variations, and disease mechanisms, which aids in understanding the bases of genetic diseases and developing targeted therapies.

The primary types of nucleic acid amplification testing include target amplification systems, probe amplification systems, and signal amplification systems. Target amplification systems are methods used to amplify specific nucleic acid sequences in a sample, crucial for improving the sensitivity and accuracy of NAAT. Product types in this field include consumables and instruments or systems featuring various technologies, such as polymerase chain reaction (PCR) tests, isothermal nucleic acid amplification technology (INAAT) tests, and ligase chain reaction (LCR) tests. NAAT is utilized in numerous applications, including infectious disease testing, oncology testing, genetic and mitochondrial disease testing, among others, and is employed by various end-users such as hospitals, diagnostic laboratories, biotechnology companies, and others.

The nucleic acid amplification testing market research report is one of a series of new reports that provides nucleic acid amplification testing market statistics, including nucleic acid amplification testing industry global market size, regional shares, competitors with a nucleic acid amplification testing market share, detailed nucleic acid amplification testing market segments, market trends and opportunities, and any further data you may need to thrive in the nucleic acid amplification testing industry. This nucleic acid amplification testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The nucleic acid amplification testing (NAAT) market consists of revenue earned by entities by provide services such as genetic disorder screening, environmental testing, infectious disease diagnosis, and pharmacogenomics. The market value includes the value of related goods sold by the service provider or included within the service offering. The nucleic acid amplification testing (NAAT) market also includes sales of reagents, pre-packaged kits, test tubes, pipettes, and plates. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.